ENTPD1 and neoplasm: Even if the A2AR inhibitor re-sensitizes immune Teff cells in TME, the immune exhaustion could be irreversible, limiting the application of AR modulators in immunotherapy-resistant tumours such as those with dominant A2AR/CD73/CD39 axis [206].